Seres Therapeutics (NASDAQ: MCRB) — Perfil da empresa, notícias e dados financeiros
ESGL Holdings transforms industrial waste into reusable products, promoting a circular economy with innovative technologies.

Seres Therapeutics
Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on transforming the lives of patients by targeting the microbiome to treat disease and improve human health. It is at the forefront of microbiome therapeutics, advancing a novel class of biological drugs. Seres is engaged in developing a portfolio of product candidates designed to restore the natural ecology of the human microbiome for patients affected by serious diseases. Their projects include therapies for conditions such as Clostridioides difficile infection, ulcerative colitis, and others within the gastrointestinal disease area. The company's objective is to lead in microbiome therapeutics by advancing science and exploring new treatment modalities for a range of diseases linked to the dysfunction of the microbiome.
Resumo
Operações
Produtos e/ou serviços de Seres Therapeutics
- SER-109, an oral microbiome therapeutic for reducing recurrent Clostridioides difficile infection (CDI).
- SER-287, an oral microbiome treatment for active mild-to-moderate ulcerative colitis.
- SER-401, a microbiome therapeutic for improving outcomes in melanoma patients undergoing immunotherapy.
- SER-301, an engineered microbiome therapeutic for inflammatory bowel disease.
- SER-262, the first synthetically derived microbiome therapeutic aimed at preventing CDI recurrence.
- Collaborative research projects with leading pharmaceutical companies to develop microbiome-based therapies for various indications.
equipe executiva do Seres Therapeutics
- Richard N. KenderInterim CEO & Executive Chair
- Matthew R. HennPresident & Chief Scientific Officer
- Marella ThorellExecutive VP, CFO & Treasurer
- Thomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
- Kelly BradyExecutive VP & COO
- Chris McChalicherExecutive VP & CTO
- Dennis M. WallingSenior VP of Clinical Development & Head of Clinical Research
- Ann KurowskiSenior Vice President of Regulatory Affairs
Últimas notícias sobre a Seres Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Seres Therapeutics, em USD.
- Cap. de mercado
- 18,1 mi
- Receita (TTM)
- 1,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 789 mil | -94 mi | 5,7 mi | |
| 0 | -121,3 mi | -146,6 mi | |
| 126,3 mi | -195,1 mi | -113,7 mi | |
| 7,1 mi | -179,9 mi | -250,2 mi |